MCID: LTR001
MIFTS: 56

Lateral Sclerosis

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 72
Primary Lateral Sclerosis 12 75 53 54
Adult-Onset Primary Lateral Sclerosis 12 53
Motor Neuron Disease 44 72
Adult-Onset Pls 53

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD9CM 35 335.24
MeSH 44 D016472
NCIt 50 C129933
SNOMED-CT 68 81211007
ICD10 33 G12.23
UMLS 72 C0085084 C0154682

Summaries for Lateral Sclerosis

NIH Rare Diseases : 53 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity, and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS, is caused by changes (mutations) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, adult, 1 and amyotrophic lateral sclerosis 4, juvenile, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is ALS2 (Alsin Rho Guanine Nucleotide Exchange Factor ALS2), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Mexiletine and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and testes, and related phenotypes are no effect and behavior/neurological

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : 75 Primary lateral sclerosis (PLS) is a rare neuromuscular disease characterized by progressive muscle... more...

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 911)
# Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, adult, 1 35.3 SOD1 ALS2
2 amyotrophic lateral sclerosis 4, juvenile 35.3 SETX ALS2
3 amyotrophic lateral sclerosis 16, juvenile 35.2 SOD1 SIGMAR1 ALS2
4 amyotrophic lateral sclerosis 2, juvenile 35.2 SOD1 ALS2
5 amyotrophic lateral sclerosis type 6 35.1 TARDBP SETX FUS ALS2
6 amyotrophic lateral sclerosis 18 35.1 TARDBP SOD1 FUS C9orf72
7 amyotrophic lateral sclerosis type 5 35.0 SPG11 ALS2
8 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.9 TARDBP SETX FUS FIG4 ALS2
9 amyotrophic lateral sclerosis 11 34.9 TARDBP SETX FUS FIG4 ALS2
10 amyotrophic lateral sclerosis 9 34.8 TARDBP SETX FUS FIG4 ALS2
11 amyotrophic lateral sclerosis 20 34.8 HNRNPA1 ALS2
12 amyotrophic lateral sclerosis 7 34.8 TARDBP SETX FUS FIG4 ALS2
13 amyotrophic lateral sclerosis type 14 34.6 VCP VAPB UBQLN2 TARDBP FUS
14 juvenile amyotrophic lateral sclerosis 34.5 SPG11 SIGMAR1 SETX FUS ALS2
15 amyotrophic lateral sclerosis 21 34.5 VCP VAPB TARDBP SOD1 SETX FUS
16 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 34.4 VCP UBQLN2 TBK1 TARDBP FUS CHCHD10
17 inclusion body myopathy with paget disease of bone and frontotemporal dementia 33.5 VCP TARDBP
18 perry syndrome 33.3 TARDBP DCTN1 C9orf72
19 progressive muscular atrophy 33.3 TARDBP C9orf72
20 distal hereditary motor neuropathies 32.8 SETX DCTN1
21 frontotemporal dementia 32.4 VCP UBQLN2 TBK1 TARDBP SOD1 NEFH
22 behavioral variant of frontotemporal dementia 31.7 VCP C9orf72
23 motor neuron disease 31.6 VCP VAPB TBK1 TARDBP SOD1 SIGMAR1
24 spinal muscular atrophy 31.3 VAPB SIGMAR1 HNRNPA1 CHCHD10
25 semantic dementia 31.2 TARDBP C9orf72
26 hereditary spastic paraplegia 31.2 VCP SPG11 SETX ALS2
27 progressive non-fluent aphasia 31.2 VCP C9orf72
28 postpoliomyelitis syndrome 30.8 VCP TARDBP
29 brown-vialetto-van laere syndrome 30.7 UBQLN2 TARDBP SOD1 C9orf72 ALS2
30 charcot-marie-tooth disease 30.4 VCP SPG11 SETX NEFH FIG4 DCTN1
31 nervous system disease 30.2 TBK1 TARDBP SOD1 C9orf72
32 dementia 30.1 VCP UBQLN2 TRPM7 TBK1 TARDBP HNRNPA1
33 central nervous system disease 29.8 TBK1 TARDBP SOD1
34 lethal congenital contracture syndrome 1 29.8 TARDBP FUS
35 amyotrophic lateral sclerosis 1 29.8 VCP VAPB UBQLN2 TRPM7 TBK1 TARDBP
36 primary lateral sclerosis, juvenile 12.9
37 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 12.9
38 madras motor neuron disease 12.8
39 amyotrophic lateral sclerosis 8 12.8
40 amyotrophic lateral sclerosis 17 12.8
41 amyotrophic lateral sclerosis 12 12.8
42 amyotrophic lateral sclerosis 14 with or without frontotemporal dementia 12.8
43 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 12.8
44 amyotrophic lateral sclerosis 19 12.8
45 amyotrophic lateral sclerosis 3 12.8
46 amyotrophic lateral sclerosis 23 12.8
47 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 12.8
48 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 12.8
49 amyotrophic lateral sclerosis 15 with or without frontotemporal dementia 12.8
50 amyotrophic lateral sclerosis 24 12.7

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, myoclonus, hemiplegia, muscular fasciculation

GenomeRNAi Phenotypes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ALS2 C9orf72 CHCHD10 DCTN1 FIG4 FUS

MGI Mouse Phenotypes related to Lateral Sclerosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 ALS2 C9orf72 DCTN1 FIG4 NEFH RNF19A
2 cellular MP:0005384 10.03 C9orf72 CHCHD10 DCTN1 NEFH RNF19A SETX
3 immune system MP:0005387 9.85 ALS2 C9orf72 DCTN1 FIG4 SETX SOD1
4 muscle MP:0005369 9.5 ALS2 DCTN1 FIG4 SOD1 TARDBP VAPB
5 nervous system MP:0003631 9.44 ALS2 C9orf72 DCTN1 FIG4 NEFH PRPH

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
2
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
3 Anti-Inflammatory Agents Phase 4
4
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
5
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
6
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
7
Ethanol Approved Phase 3 64-17-5 702
8
Citalopram Approved Phase 3 59729-33-8 2771
9
Mecasermin Approved, Investigational Phase 3 68562-41-4
10
Zinc Approved, Investigational Phase 3 7440-66-6 32051
11
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
12
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
13
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
14
Methylcobalamin Approved, Experimental, Investigational Phase 3 13422-55-4
15
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
16
Sodium citrate Approved, Investigational Phase 3 68-04-2
17
Edaravone Approved, Investigational Phase 2, Phase 3 89-25-8 70335
18
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
19
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
20
Pramipexole Approved, Investigational Phase 3 104632-26-0 59868 119570
21
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
22
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
23
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
24
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
26
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
28
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
30
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
31 Nabiximols Investigational Phase 2, Phase 3 56575-23-6
32 Tocotrienol Investigational Phase 3 6829-55-6
33
Cobalamin Experimental Phase 3 13408-78-1 6857388
34
Ibudilast Investigational Phase 2, Phase 3 50847-11-5 3671
35 Simendan Investigational Phase 3 131741-08-7
36 Retinol palmitate Phase 2, Phase 3
37 retinol Phase 2, Phase 3
38 Peripheral Nervous System Agents Phase 3
39 Adjuvants, Immunologic Phase 2, Phase 3
40 Anti-Bacterial Agents Phase 3
41 Neuromuscular Agents Phase 3
42 abobotulinumtoxinA Phase 2, Phase 3
43 rimabotulinumtoxinB Phase 2, Phase 3
44 Botulinum Toxins, Type A Phase 2, Phase 3
45 Antibodies Phase 3
46 Immunoglobulins Phase 3
47 Hypoglycemic Agents Phase 3
48 Parasympatholytics Phase 3
49 Antidepressive Agents, Second-Generation Phase 3
50 insulin Phase 3

Interventional clinical trials:

(show top 50) (show all 598)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study Completed NCT00614926 Phase 4 Modafinil;Placebo
6 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
7 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
8 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
9 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
10 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
11 A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
12 The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
13 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
14 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
15 A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
16 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
17 Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
18 A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
19 An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
20 Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2 Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
21 A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
22 An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
23 An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT01285583 Phase 2, Phase 3 TRO19622
24 A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
25 An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis Completed NCT00965497 Phase 3 escitalopram
26 Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
27 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
28 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
29 Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. Completed NCT00372879 Phase 3
30 A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS Completed NCT00136110 Phase 3 Sodium Valproate
31 A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT02496767 Phase 3 tirasemtiv;Placebo tablets;Riluzole 50 MG
32 Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT00868166 Phase 3 Olesoxime;Placebo Comparator;Riluzole
33 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
34 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
35 A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
36 Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS) Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
37 Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00349622 Phase 3 ceftriaxone
38 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
39 Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
40 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
41 Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study Completed NCT01257828 Phase 3 riluzole;Placebo medication
42 Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment Completed NCT00146809 Phase 3 Minocyline
43 Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia Completed NCT02350127 Phase 2, Phase 3
44 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
45 A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia Completed NCT00733057 Phase 3 Minocycline;Placebo (200 mg/day)
46 Open Label, Non-randomized Extension Trial to Assess Long Term Safety and Efficacy of Arimoclomol in Subjects With Amyotropic Lateral Sclerosis Who Have Completed the ORARIALS-01 Trial Recruiting NCT03836716 Phase 3 Arimoclomol
47 Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study Recruiting NCT03548311 Phase 3 methylcobalamin;saline solution
48 A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (CannTrust CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients Recruiting NCT03690791 Phase 3 CannTrust CBD Oil (capsule);Placebo (capsule)
49 Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT03800524 Phase 3 Tauroursodeoxycholic Acid;Placebo
50 A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation Recruiting NCT02623699 Phase 3 BIIB067

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

41
Brain, Spinal Cord, Testes, Cortex, Bone, Skeletal Muscle, Skin

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 21705)
# Title Authors PMID Year
1
Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). 38
31384636 2019
2
Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment. 38
31397342 2019
3
Communication change in ALS: engaging people living with ALS and their partners in future research. 38
30284928 2019
4
β-catenin aggregation in models of ALS motor neurons: GSK3β inhibition effect and neuronal differentiation. 38
31176720 2019
5
Modified age-dependent expression of NaV1.6 in an ALS model correlates with motor cortex excitability alterations. 38
31302244 2019
6
New pathologic mechanisms in nucleotide repeat expansion disorders. 38
31229686 2019
7
Myelin degeneration induced by mutant superoxide dismutase 1 accumulation promotes amyotrophic lateral sclerosis. 38
31290185 2019
8
Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation. 38
30939964 2019
9
Predicting disease specific spinal motor neurons and glia in sporadic ALS. 38
31276795 2019
10
Non-genetically modified models exhibit TARDBP mRNA increase due to perturbed TDP-43 autoregulation. 38
31310801 2019
11
Neuronal TDP-43 depletion affects activity-dependent plasticity. 38
31176717 2019
12
Amyotrophic Lateral Sclerosis-associated GGGGCC repeat expansion promotes Tau phosphorylation and toxicity. 38
31176718 2019
13
ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis. 38
30861116 2019
14
Strong-Weak Pruning for Brain Network Identification in Connectome-Wide Neuroimaging: Application to Amyotrophic Lateral Sclerosis Disease Stage Characterization. 38
30929575 2019
15
Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. 38
31325668 2019
16
Motor cortex metabolite alterations in amyotrophic lateral sclerosis assessed in vivo using edited and non-edited magnetic resonance spectroscopy. 38
31002818 2019
17
Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period. 38
31233613 2019
18
Air contamination during medical treatment results in deposits of microemboli in the lungs: An autopsy study. 38
30973284 2019
19
Survival prediction models in motor neuron disease. 38
30920076 2019
20
New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation. 38
31034795 2019
21
A hyperthermophilic protein G variant engineered via directed evolution prevents the formation of toxic SOD1 oligomers. 38
31017342 2019
22
A Novel Pharyngeal Clearance Maneuver for Initial Tracheostomy Tube Cuff Deflation in High Cervical Tetraplegia. 38
30973517 2019
23
Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis. 38
30760643 2019
24
The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients. 38
31382080 2019
25
The 'neurophysiological index' predicts survival in amyotrophic lateral sclerosis. 38
31213354 2019
26
Motor unit number index and compound muscle action potential amplitude. 38
31288985 2019
27
Elevated FUS levels by overriding its autoregulation produce gain-of-toxicity properties that disrupt protein and RNA homeostasis. 38
31230528 2019
28
Neurodegenerative disorders and sterile inflammation: lessons from a Drosophila model. 38
31251338 2019
29
Type II diabetes mellitus and the incidence of amyotrophic lateral sclerosis. 38
31152300 2019
30
Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis. 38
31164255 2019
31
Rational discovery of a SOD1 tryptophan oxidation inhibitor with therapeutic potential for amyotrophic lateral sclerosis. 38
30286701 2019
32
Poor emotional well-being is associated with rapid progression in amyotrophic lateral sclerosis. 38
31384673 2019
33
Fungal-contaminated grass and well water and sporadic amyotrophic lateral sclerosis. 38
31089037 2019
34
Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons. 38
30944974 2019
35
In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. 38
31102766 2019
36
Adipose-derived stem cell conditioned medium for the treatment of amyotrophic lateral sclerosis: pre-clinical evidence and potential for clinical application. 38
31089048 2019
37
Cholinergic modulation of motor neurons through the C-boutons are necessary for the locomotor compensation for severe motor neuron loss during amyotrophic lateral sclerosis disease progression. 38
31022419 2019
38
Novel behavioural characteristics of the superoxide dismutase 1 G93A (SOD1G93A ) mouse model of amyotrophic lateral sclerosis include sex-dependent phenotypes. 38
31412164 2019
39
Facial nerve atrophy in patients with amyotrophic lateral sclerosis: Evaluation with fast imaging employing steady-state acquisition (FIESTA). 38
31400058 2019
40
Value of fluid-attenuated inversion recovery MRI data analyzed by the lesion segmentation toolbox in amyotrophic lateral sclerosis. 38
30569457 2019
41
Impaired Pentose Phosphate Pathway in the Spinal Cord of the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. 38
30685842 2019
42
Whole-exome sequencing identified novel KIF5A mutations in Chinese patients with amyotrophic lateral sclerosis and Charcot-Marie-Tooth type 2. 38
31422367 2019
43
Rational design of linear tripeptides against the aggregation of human mutant SOD1 protein causing amyotrophic lateral sclerosis. 38
31422280 2019
44
Characterizing TDP-43(307-319) Oligomeric Assembly : Mechanistic and Structural Implications Involved in the Etiology of Amyotrophic Lateral Sclerosis. 38
31430111 2019
45
Hyperexcitability in Cultured Cortical Neuron Networks from the G93A-SOD1 Amyotrophic Lateral Sclerosis Model Mouse and its Molecular Correlates. 38
31400485 2019
46
The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. 38
31116037 2019
47
Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. 38
31131638 2019
48
MScanFit motor unit number estimation (MScan) and muscle velocity recovery cycle recordings in amyotrophic lateral sclerosis patients. 38
31163374 2019
49
Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and small heat shock protein expression in reactive astrocytes. 38
30346063 2019
50
re: "Facial nerve atrophy in patients with amyotrophic lateral sclerosis: Evaluation with fast imaging employing steady-state acquisition (FIESTA)". 38
31397967 2019

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 TARDBP SOD1 SIGMAR1 NEFH DCTN1
2
Show member pathways
11.37 PRPH NEFH DCTN1
3
Show member pathways
10.98 SOD1 PRPH NEFH ALS2

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasmic vesicle GO:0031410 9.72 UBQLN2 SPG11 SOD1 SIGMAR1 C9orf72
2 lipid droplet GO:0005811 9.43 VCP SIGMAR1 FIG4
3 growth cone GO:0030426 9.26 SIGMAR1 SETX C9orf72 ALS2
4 axon GO:0030424 9.1 SPG11 SETX NEFH DCTN1 C9orf72 ALS2
5 cytoplasm GO:0005737 10.03 VCP VAPB UBQLN2 TBK1 TARDBP SPG11

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.33 SOD1 FIG4 ALS2
2 axon extension GO:0048675 9.26 SPG11 C9orf72
3 regulation of autophagosome assembly GO:2000785 8.96 UBQLN2 C9orf72
4 neurofilament cytoskeleton organization GO:0060052 8.62 SOD1 NEFH

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 VCP VAPB UBQLN2 TBK1 TARDBP SPG11
2 identical protein binding GO:0042802 9.43 VCP TBK1 TARDBP SOD1 SETX FUS
3 dynein complex binding GO:0070840 9.16 NEFH DCTN1

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....